comparemela.com

Latest Breaking News On - Extension phase - Page 2 : comparemela.com

89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)

Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests of liver injury/inflammation and.

89bio s Fatty Liver Candidate Shows Long-Term Improvement: Details - 89bio (NASDAQ:ETNB)

89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with 

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.